Bay Harbor Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bay Harbor Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.83K	Buy	32 +7	+28%	+$383	﹤0.01%	676
2026 Q1	$1.41K	Buy	25 +11	+79%	+$641	﹤0.01%	651
2025 Q4	$832	Buy	14 +4	+40%	+$218	﹤0.01%	689
2025 Q3	$541	Buy	10 +1	+11%	+$57	﹤0.01%	701
2025 Q2	$494	Buy	9 +5	+125%	+$294	﹤0.01%	650
2025 Q1	$282	Buy	+4	New	+$269	﹤0.01%	571
2020 Q4	–	Sell	-42	Closed	-$3K	–	416
2020 Q3	$3K	Buy	+42	New	+$4.25K	﹤0.01%	281

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Bay Harbor Wealth Management's BMRN Position: Q2 2026 in Review

Bay Harbor Wealth Management increased its BioMarin Pharmaceuticals (BMRN) stake by 28% in Q2 2026, buying an estimated $383 and bringing the position to 32 shares worth $1.83K. The position accounts for ﹤0.01% of the portfolio, ranked #676.

Bay Harbor Wealth Management first reported a position in BMRN in Q3 2020 and has held it in 7 quarters since. The position peaked at $3K in Q3 2020. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Bay Harbor Wealth Management held 32 shares of BioMarin Pharmaceuticals worth $1.83K as of Q2 2026.
Bay Harbor Wealth Management bought 7 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $383.
BioMarin Pharmaceuticals made up ﹤0.01% of Bay Harbor Wealth Management's portfolio in Q2 2026, its #676 holding.
Bay Harbor Wealth Management first reported a position in BioMarin Pharmaceuticals in Q3 2020 and has held it in 7 quarters since.
Bay Harbor Wealth Management's BioMarin Pharmaceuticals position peaked at $3K in Q3 2020.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Bay Harbor Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.